FEDERAL COURT OF AUSTRALIA
Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2
Citation: Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2 Appeal from: Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114
Bristol-Myers Squibb Company v Apotex Pty Ltd (No 6) [2013] FCA 1235
Parties: BRISTOL-MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO LTD v APOTEX PTY LTD ACN 096 916 148
APOTEX PTY LTD ACN 096 916 148 v BRISTOL‑MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO LTD
File numbers: NSD 2526 of 2013
NSD 2535 of 2013Judges: BESANKO, JAGOT, NICHOLAS JJ Date of judgment: 23 January 2015 Catchwords: PATENTS – construction – where specification disclosed chemical substance – whether specification disclosed chemical substance with a particular crystalline form or a chemical substance having certain characteristics.
PATENTS – lack of novelty – whether invention claimed in patent anticipated by the prior art – whether the person skilled in the art would inevitably have taken particular drying steps required to create the invention in following directions in the prior art – whether the prior art discloses the particular crystalline form of chemical substance claimed and whether that disclosure discloses the properties of the invention claimed in the patent.
PATENTS – lack of inventive step – whether invention claimed in patent obvious – whether the person skilled in the art would have, as a matter of routine at the relevant time, dried chemical product in required manner to create particular chemical substance claimed – whether evidence of expert instructed to carry out experiment can satisfy the modified Cripps question.
PATENTS – exclusive licences – whether agreement between patentee and licensee an exclusive licence – where licensee granted exclusive rights to advertise, market, promote, sell and distribute invention, but patentee reserved exclusive rights to manufacture the invention – Patents Act 1990 (Cth) s 13(1), Schedule 1.
Held: Appeals dismissed. Patent not invalid. Licence not exclusive licence for purposes of the Patents Act 1990 (Cth).
Legislation: Patents Act 1949 (UK) s 101
Patents Act 1952 (Cth) s 95
Patents Act 1990 (Cth) ss 7, 13, 120, Schedule 1Cases cited: Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416; [2009] FCAFC 134
AstraZenenca AB v Apotex Pty Ltd [2014] FCAFC 99
Blue Gentian LLC v Product Management Group Pty Ltd [2014] FCA 1331
Bristol-Myers Squibb Company v Apotex Pty Ltd (2010) 87 IPR 516; [2010] FCA 814
Bristol-Myers Squibb Company v Apotex Pty Ltd (No 4) [2012] FCA 1433
Evans Medical Ltd’s Patent [1998] RPC 517
Ex parte British Nylon Spinners Limited and Imperial Chemicals Industries Limited; In Re Imperial Chemical Industries Limited’s Patent (1963) 109 CLR 336
Fried v National Australia Bank [2000] FCA 910
Grant and Another v Australian Temporary Fencing Pty Ltd (2003) 59 IPR 170; [2003] QSC 194
H Lundbeck A/S v Alphapharm Pty Ltd (2009) 177 FCR 151; [2009] FCAFC 70
House v The King (1936) 55 CLR 499
ICI Chemicals & Polymers Ltd v The Lubrizol Corporation…
Keep reading for free
Create a free CaseChat account to read Bristol-Myers Squibb Company v Apotex Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2015] FCAFC 2
- Decision Date
CaseChat Overview and Summary
The court had to determine whether the patent specification disclosed a chemical substance with a particular crystalline form or a chemical substance having certain characteristics. It also had to decide if the invention was anticipated by prior art and if the person skilled in the art would inevitably have taken particular drying steps required to create the invention. Additionally, the court needed to assess whether the invention lacked an inventive step and if the person skilled in the art would have, as a matter of routine, dried the chemical product in the required manner to create the particular chemical substance claimed. The court also had to consider whether expert evidence could satisfy the modified Cripps question. Lastly, the court examined whether the agreement between the parties constituted an exclusive licence under the Patents Act.
The court held that the appeals were dismissed and that the patent was not invalid. The court found that the agreement between the parties was not an exclusive licence for the purposes of the Patents Act. The court's reasoning was based on the interpretation of the definition of "exploit" and the nature of the rights granted under the agreement. The court concluded that the primary judge's construction of the word "exploit" was correct and consistent with the High Court's reasoning in British Nylon Spinners. The court also found that the agreement did not confer exclusive rights to manufacture the invention, which was a key factor in determining whether it was an exclusive licence.
The court's final orders were that the appeals be dismissed and that the appellants pay the respondents' costs of the appeal. The court emphasised that the entry of orders was dealt with in Rule 39.32 of the Federal Court Rules 2011.
Orders
Orders of the court
1. The appeal be dismissed.
2. The appellants pay the respondent’s costs of the appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
1. The appeal be dismissed.
2. The appellant pay the respondents’ costs of the appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi